FDA CRDAC: Novartis' serelaxin not ready for prime time
This article was originally published in Scrip
Executive Summary
Advisers to the FDA were solidly unanimous in rejecting Novartis' serelaxin (RLX030), a relaxin receptor agonist, as a treatment for acute heart failure (AHF) at a 27 March meeting, which at one point got downright prickly between one of the panelists and the drug maker's key outside expert consultant, who often shares a seat on the same committee.